Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (COBALT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00499590
Recruitment Status : Terminated
First Posted : July 11, 2007
Results First Posted : October 6, 2014
Last Update Posted : October 6, 2014
Information provided by (Responsible Party):
OPKO Health, Inc.

Brief Summary:
The purpose of this study is to compare the safety and effectiveness of bevasiranib given either every 8 weeks or every 12 weeks after an initial pre-treatment with 3 injections of Lucentis® (ranibizumab injection) compared to Lucentis® given every 4 weeks to people with wet AMD. Patients will be assigned at random (like tossing a coin) to receive one of three treatments options for 104 weeks.

Condition or disease Intervention/treatment Phase
Macular Degeneration Drug: bevasiranib Drug: ranibizumab Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 338 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-masked, Parallel-assignment Study of Intravitreal Bevasiranib Sodium, Administered Every 8 or 12 Weeks as Maintenance Therapy Following Three Injections of Lucentis® Compared With Lucentis® Monotherapy Every 4 Weeks in Patients With Exudative Age-Related Macular Degeneration (AMD).
Study Start Date : August 2007
Actual Primary Completion Date : March 2009
Actual Study Completion Date : May 2009

Resource links provided by the National Library of Medicine

Drug Information available for: Ranibizumab

Arm Intervention/treatment
Active Comparator: A
Lucentis® (0.5mg) every 4 weeks.
Drug: ranibizumab
Lucentis® (0.5 mg)administered intravitreally every 4 weeks.
Other Name: Lucentis®

Experimental: B
Bevasiranib (2.5mg) every 8 weeks beginning at week 12, after pre-treatment with 3 injections of Lucentis® and initial priming doses of bevasiranib at weeks 2 & 6.
Drug: bevasiranib
Bevasiranib (2.5mg) administered intravitreally every 8 or 12 weeks

Experimental: C
Bevasiranib (2.5mg) every 12 weeks beginning at week 12, after pre-treatment with 3 injections of Lucentis® and initial priming doses of bevasiranib at weeks 2 & 6.
Drug: bevasiranib
Bevasiranib (2.5mg) administered intravitreally every 8 or 12 weeks

Primary Outcome Measures :
  1. Visual Acuity [ Time Frame: week 60 ]
    avoidance of 3 or more lines of vision loss

Secondary Outcome Measures :
  1. Need for Rescue Therapy, Time to Rescue Therapy, and Number of Patients With a 3 or More Line Gain in Vision [ Time Frame: Week 60 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients must be age 50 years or older
  2. Patients must have predominantly classic, minimally classic or occult with no classic lesions secondary to Age Related Macular Degeneration.
  3. The study eye must have ETDRS best corrected visual acuity of 69 to 24 letters (20/40 to 20/320 Snellen equivalent).
  4. Patients must be willing and able to return for scheduled monthly follow-up visits for two-years.

Exclusion Criteria:

  1. Prior pharmacologic treatment for AMD in the study (patients can not have previously received Avastin®/Lucentis®, Macugen®, or any other anti-VEGF agents, steroid treatments, PDT, radiation treatment, or any experimental therapies for AMD in the study eye)
  2. Any intraocular surgery of the study eye within 12 weeks of screening
  3. Previous posterior vitrectomy of the study eye
  4. Advanced glaucoma or intraocular pressure above 22 mm Hg in the study eye despite treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00499590

  Hide Study Locations
United States, Arizona
Retinal Consultants of Arizona (site 209)
Phoenix, Arizona, United States, 85014
Associated Retina Consultants (site 286)
Phoenix, Arizona, United States, 85020
Retina Centers PC (site 215)
Tucson, Arizona, United States, 85704
United States, California
Eye Medical Center (site 287)
Fresno, California, United States, 93720
Northern California Retina Vitreous Associates (site 320)
Mountain View, California, United States, 94040
Retina Institute of California (site 207)
Pasadena, California, United States, 91105
Retina Consultants San Diego (site 232)
Poway, California, United States, 93064
Retinal Consultants Medical Group (site 289)
Sacramento, California, United States, 95819
Orange County Retina Medical Group (site 252)
Santa Ana, California, United States, 92705
Miramar Eye Specialists Medical Group (site 245)
Ventura, California, United States, 93003
United States, Connecticut
The Eye Care Group, PC (site 315)
Waterbury, Connecticut, United States, 06708
United States, Florida
Florida Eye Clinic (site 257)
Altamonte Springs, Florida, United States, 32701
Florida Eye Microsurgical Institute, Inc. (site 217)
Boynton Beach, Florida, United States, 33426
Retina Health Center (site 247)
Fort Myers, Florida, United States, 33901
National Ophthalmic Research Institute at Retina Consultants of SW Florida (site 270)
Fort Myers, Florida, United States, 33912
Magruder Eye Institute (site 264)
Orlando, Florida, United States, 32803
Southern Vitreoretinal Associates, PL (site 309)
Tallahassee, Florida, United States, 32308
University of South Florida Eye Institute (site 311)
Tampa, Florida, United States, 33612
Center for Retina and Macular Disease (site 293)
Winter Haven, Florida, United States, 33880
United States, Georgia
Southeast Retina Center (site 268)
Augusta, Georgia, United States, 30909
United States, Indiana
Midwest Eye Institute (site 253)
Indianapolis, Indiana, United States, 46280
United States, Kansas
Retina Associates, PA (site 295)
Shawnee Mission, Kansas, United States, 66204
Vitreo-Retinal Consultants & Surgeons, P.A. (site 274)
Wichita, Kansas, United States, 67214
United States, Kentucky
Eye Centers of Louisville (site 251)
Louisville, Kentucky, United States, 40207
United States, Maryland
Retina Specialists (site 231)
Towson, Maryland, United States, 21204
United States, Missouri
Retina Associates St. Louis (site 300)
Florissant, Missouri, United States, 63031
Eye Foundation of Kansas City Truman Medical Center (site 272)
Kansas City, Missouri, United States, 64108
United States, Nevada
Retinal Consultants of Nevada (site 273)
Las Vegas, Nevada, United States, 89144
United States, New Hampshire
Eyesight Ophthalmic Services, PA (site 290)
Portsmouth, New Hampshire, United States, 03801
United States, New Jersey
Delaware Valley Retina Associates (site 261)
Lawrenceville, New Jersey, United States, 08648
Retina-Vitreous Consultants (site 216)
Livingston, New Jersey, United States, 07039
Retina Associates of New Jersey (site 298)
Teaneck, New Jersey, United States, 07666
United States, New York
Capital Region Retina (site 316)
Albany, New York, United States, 12206
New York Eye & Ear Infirmary (site 272)
New York, New York, United States, 10003
Vitreous-Retina-Macula Consultants of New York (site 239)
New York, New York, United States, 10022
United States, North Carolina
Carolina Eye Associates (site 308)
Southern Pines, North Carolina, United States, 28387
United States, Ohio
Retina Associates of Cleveland (site 228)
Beachwood, Ohio, United States, 44122
Cincinnati Eye Institute (site 285)
Cincinnati, Ohio, United States, 45242
Retina Associates of Cleveland, Inc. (site 219)
Lakewood, Ohio, United States, 44107
Retina-Vitreous Associates (site 266)
Toledo, Ohio, United States, 43608
United States, Oregon
Retina and Vitreous Center of Southern Oregon (site 271)
Ashland, Oregon, United States, 97520
United States, Pennsylvania
Ophthalmology Associates of PA (site 297)
Bala Cynwyd, Pennsylvania, United States, 19004
United States, South Carolina
Palmetto Retina Center (site 275)
West Columbia, South Carolina, United States, 29169
United States, South Dakota
Black Hills Regional Eye Institute (site 202)
Rapid City, South Dakota, United States, 57701
United States, Tennessee
Southeastern Retina Associates, PC (Site 250)
Knoxville, Tennessee, United States, 37909
United States, Texas
Retina Research Institute of Texas, L.L.C. (site 269)
Abilene, Texas, United States, 79606
Austin Retina Associates (site 304)
Austin, Texas, United States, 78705
Retina Research Center (site 204)
Austin, Texas, United States, 78705
University of Texas Medical Branch- Galveston (site 301
Galveston, Texas, United States, 77555
Houston Eye Associates (site 321)
Houston, Texas, United States, 77025
Valley Retina Institue, PA (site 258)
McAllen, Texas, United States, 78503
Eye Care Associates of East Texas (site 282)
Tyler, Texas, United States, 75701
United States, Utah
Rocky Mountain Retina Consultants (site 256)
Salt Lake City, Utah, United States, 84107
University of Utah, John A. Moran Eye Center (site 205)
Salt Lake City, Utah, United States, 84132
United States, Virginia
University of Virginia- Ophthalmology Dept. (site 254)
Charlottesville, Virginia, United States, 22908
Canada, Alberta
Calgary Retina Consultants (site 318)
Calgary, Alberta, Canada, T3E 7M8
Canada, Ontario
Ivey Eye Institute (site 314)
London, Ontario, Canada, N6A 4G5
Canadian Centre for Advanced Eye Therapeutics (site 291)
Mississauga, Ontario, Canada, L4W 1W9
Sunnybrook Health Sciences Centre (site 305)
Toronto, Ontario, Canada, M4N 3M5
Canada, Saskatchewan
Eye Centre Pasqua Hospital (site 299)
Regina, Saskatchewan, Canada, S4T 1A5
Sponsors and Collaborators
OPKO Health, Inc.
Study Director: Denis O'Shaughnessy, Ph.D. Senior VP of Clincial Development

Responsible Party: OPKO Health, Inc. Identifier: NCT00499590     History of Changes
Other Study ID Numbers: ACU301
First Posted: July 11, 2007    Key Record Dates
Results First Posted: October 6, 2014
Last Update Posted: October 6, 2014
Last Verified: September 2014

Keywords provided by OPKO Health, Inc.:
Macular Degeneration
COBALT study
age related macular degeneration
wet AMD
wet age related macular degeneration

Additional relevant MeSH terms:
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents